Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 16 Jun, 07:07 pm

Jabil is strategically positioned in high-growth sectors like AI infrastructure and healthcare , expanding its partnerships in advanced technologies. The company is set to release its quarterly earnings report on June 17, 2026, with analysts estimating an EPS of $3.09 and revenue

Stoke Therapeutics' capital efficiency is assessed by comparing its Return on Invested Capital (ROIC) to its Weighted Average Cost of Capital (WACC). Despite a negative ROIC, common for clinical-stage biopharma companies, Stoke Therapeutics' ROIC/WACC ratio stands at -4.63 . Stok
Headlines provided by Investing.com